Common use
Pletal (generic name: cilostazol) is indicated to reduce symptoms of intermittent claudication, the cramping leg pain caused by peripheral arterial disease (PAD) during walking or exercise. By inhibiting phosphodiesterase III (PDE3), cilostazol increases cyclic AMP in platelets and vascular smooth muscle, leading to antiplatelet effects and vasodilation. The net result is improved blood flow to the legs and enhanced walking distance with less discomfort.
Pletal is typically used alongside foundational PAD management, including smoking cessation, structured exercise programs, lipid and blood pressure control, and antiplatelet therapy as advised by your clinician. Patients often notice improvement within 2–4 weeks, with maximal benefit by around 12 weeks. If no meaningful response is seen after three months, clinicians often reassess whether to continue therapy.
Important note: Pletal is contraindicated in heart failure of any severity due to increased mortality observed with PDE3 inhibitors in that population. It should only be used when the benefits outweigh risks and when safer alternatives are not suitable.
Dosage and direction
The typical adult dosage for intermittent claudication is 100 mg orally twice daily. For best absorption and to minimize side effects, take Pletal consistently either 30 minutes before or 2 hours after breakfast and dinner. Taking with a high-fat meal can increase drug levels and the likelihood of adverse effects, so the fasting window is recommended.
Dose adjustments are needed when Pletal is combined with certain medicines that affect its metabolism (notably CYP3A4 or CYP2C19 inhibitors). When used with strong or moderate inhibitors (for example, ketoconazole, erythromycin, clarithromycin, diltiazem, verapamil, omeprazole, fluconazole), clinicians often reduce the dose to 50 mg twice daily to limit side effects while maintaining efficacy.
Therapy is usually continued for up to 12 weeks before determining whether benefit warrants ongoing use. If meaningful improvement is not observed, discontinuation may be considered. Always follow your clinician’s guidance and do not change dose or stop the medication without medical advice.
Smoking can blunt the therapeutic effect of cilostazol. Patients are strongly encouraged to quit tobacco and enroll in supervised exercise therapy to maximize the walking-distance benefit of Pletal.
Precautions
Cardiovascular risk: Because Pletal increases heart rate and has inotropic effects, it is contraindicated in heart failure and should be used with caution in patients with arrhythmias, coronary artery disease, or recent myocardial infarction. Report palpitations, chest pain, shortness of breath, syncope, or new swelling immediately.
Bleeding risk: Cilostazol’s antiplatelet activity, especially when combined with aspirin, clopidogrel, anticoagulants, or NSAIDs, increases bleeding risk. Monitor for unusual bruising, nosebleeds, gum bleeding, black/tarry stools, or blood in urine. Conditions such as active peptic ulcer disease, recent bleeding, or bleeding disorders warrant extra caution.
Hepatic and renal function: Severe hepatic impairment has not been well studied; use is generally avoided or approached with caution. While mild-to-moderate renal impairment often does not require a dose change, monitoring for side effects is prudent. Discuss your kidney and liver history with your prescriber.
Pregnancy and lactation: Safety in pregnancy and breastfeeding is not established. Use only if the potential benefit justifies potential risk. If you are pregnant, planning to become pregnant, or breastfeeding, consult your healthcare professional before starting Pletal.
Surgery and procedures: Because Pletal affects platelet function, your clinician may advise stopping it ahead of elective procedures to reduce bleeding risk. Do not discontinue without personalized guidance.
Contraindications
Absolute contraindication: Heart failure of any severity. PDE3 inhibitors have been associated with increased mortality in heart failure populations, and cilostazol carries a boxed warning reflecting this risk.
Additional contraindications include known hypersensitivity to cilostazol or any tablet component. Relative contraindications or situations requiring caution include active bleeding, severe hepatic impairment, uncontrolled arrhythmias, significant ischemic heart disease, or a history of hemorrhagic disorders. A thorough cardiovascular assessment helps determine suitability.
Possible side effects
Common side effects include headache, diarrhea, palpitations, dizziness, peripheral edema (swelling), abdominal discomfort, nausea, and tachycardia. Many of these effects are dose-related and may lessen with time or with a dose reduction when clinically appropriate.
Less common but more serious reactions can involve significant bleeding, hypotension, arrhythmias, chest pain, and hematologic effects such as thrombocytopenia or leukopenia. Seek urgent care for signs of severe bleeding, fainting, fast or irregular heartbeat, chest pressure, or shortness of breath.
Allergic reactions—rash, itching, facial or throat swelling, wheezing—require immediate medical attention. Always report persistent or severe adverse effects to your clinician, who may adjust your regimen or investigate alternatives.
Drug interactions
Metabolic interactions: Pletal is metabolized primarily by CYP3A4 and CYP2C19. Strong or moderate inhibitors of these enzymes (for example, ketoconazole, itraconazole, posaconazole, erythromycin, clarithromycin, diltiazem, verapamil, omeprazole, fluconazole) can increase cilostazol levels and side effects; dose reduction to 50 mg twice daily is commonly recommended. Inducers (such as rifampin, carbamazepine, phenytoin, or St. John’s wort) may reduce efficacy.
Antiplatelet/anticoagulant combinations: Concomitant use with aspirin, clopidogrel, prasugrel, ticagrelor, warfarin, apixaban, rivaroxaban, dabigatran, or heparins raises bleeding risk. When co-prescribed, clinicians balance benefit and risk, use the lowest effective doses, and monitor for bleeding.
Other considerations: Grapefruit and grapefruit juice may inhibit CYP3A4 and increase cilostazol exposure; many clinicians recommend avoiding grapefruit products. NSAIDs, SSRIs/SNRIs, and high-dose fish oils can contribute to bleeding risk. Always share a complete, updated list of prescription drugs, OTC medicines, vitamins, and herbal supplements with your pharmacist and prescriber.
Missed dose
If you miss a dose, take it as soon as you remember unless it is close to the time for your next dose. If it is nearly time for the next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double up to make up for a missed dose; doing so can increase side effects such as headache, palpitations, and dizziness.
Overdose
Symptoms of overdose may include severe headache, pronounced dizziness, flushing, fast or irregular heartbeat, low blood pressure, chest pain, tremors, or fainting. Because cilostazol can potentiate bleeding risk, hemorrhagic complications are also a concern in overdose scenarios.
If an overdose is suspected, call emergency services or contact Poison Control (in the U.S., 1-800-222-1222) immediately. Management is supportive: stabilize airway and circulation, monitor cardiac rhythm and blood pressure, and treat symptoms. There is no specific antidote, and hemodialysis is unlikely to be beneficial due to high protein binding.
Storage
Store Pletal tablets at controlled room temperature (20°C to 25°C / 68°F to 77°F), with permitted excursions as directed on the label. Keep in the original, tightly closed container, protected from moisture and excessive heat. As with all medicines, keep out of reach of children and pets, and properly dispose of expired or unused tablets per local guidance or pharmacy take-back programs.
U.S. Sale and Prescription Policy
In the United States, Pletal (cilostazol) is a prescription-only medication. That means a licensed prescriber must evaluate your medical history, current conditions, and medications to determine whether Pletal is appropriate and safe. Claims that you can “buy Pletal without prescription” can be misleading and may reflect noncompliant or unsafe sources. For your protection, always use licensed, verifiable channels.
HealthSouth Rehabilitation Hospital of Manati provides a legal and structured path to access Pletal by connecting you with qualified clinicians for a compliant evaluation. You do not need to bring an existing paper prescription; instead, a licensed professional reviews your health status via a secure process and, if appropriate, issues a valid prescription that is then dispensed through licensed pharmacy operations. This preserves safety, ensures the therapy fits your needs, and complies with U.S. laws.
This model is not “no-prescription-needed.” Rather, it streamlines care: you receive evidence-based guidance, screening for contraindications (such as heart failure), review of potential drug interactions (CYP3A4/CYP2C19 inhibitors, anticoagulants, antiplatelets), and clear instructions on Pletal dosage and monitoring. The result is safer access, clinical oversight, and transparent pricing.
To verify legitimacy, look for proper state licensure, secure payment systems, and availability of pharmacist counseling. Avoid websites that ship prescription drugs without a clinician’s review. If you have questions about starting or continuing cilostazol, HealthSouth Rehabilitation Hospital of Manati’s team can coordinate a compliant evaluation and, if appropriate, prescription fulfillment with ongoing support.
